<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229292</url>
  </required_header>
  <id_info>
    <org_study_id>2013-005473-52</org_study_id>
    <nct_id>NCT02229292</nct_id>
  </id_info>
  <brief_title>Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid</brief_title>
  <acronym>TXA2014-15</acronym>
  <official_title>Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of South West Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestjydsk Ortop√¶disk Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of South West Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study:&#xD;
&#xD;
        -  To evaluate the effect of tranexamic acid (TXA) of intraoperative blood loss in patients&#xD;
           subjected to bi-maxillary orthognathic surgery&#xD;
&#xD;
        -  To evaluate the potential effect of TXA on fibrin structure&#xD;
&#xD;
        -  To evaluate the potential effect of TXA of binding of plasminogen to fibrin&#xD;
&#xD;
        -  To evaluate the potential effect of TXA on postoperative edema formation.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      H0: Intraoperative bleeding cannot be significantly reduced by preoperative administration of&#xD;
      tranexamic acid&#xD;
&#xD;
      H0,1: Postoperative edema cannot be significantly reduced by preoperative administration of&#xD;
      tranexamic acid&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population consists of patients referred to simultaneous mandibular and maxillary&#xD;
      osteotomy at the Department of Oral and Maxillofacial Surgery, Hospital of South West Denmark&#xD;
      in 2014.&#xD;
&#xD;
      Hundred patients (50 men and 50 women) will be enrolled in the study. Reportedly, the mean&#xD;
      intraoperative blood loss in the placebo group is expected to be 436 ml with a standard&#xD;
      deviation of 208 ml. The difference in blood loss between the TXA-group and the placebo group&#xD;
      to be detected is 100 ml. The dropout frequency is estimated to 10%. To fulfil these&#xD;
      assumptions a minimum of 40 patients should be included in each group to reach a power of 0.8&#xD;
      and an alpha of 0.05. In order to accommodate an even gender distribution a block&#xD;
      randomization is performed resulting in the randomization of 100 patients.&#xD;
&#xD;
      The patients will be randomized to receive blindly either 10 ml tranexamic acid (100 mg/ml)&#xD;
      (Pfizer, Ballerup, Denmark) or 10 ml saline (9mg/ml) preoperatively. Intraoperative blood&#xD;
      loss will be determined by deducting the total volume of irrigation fluids from the volume of&#xD;
      the contents of the surgical suction device. Postoperative edema formation will be determined&#xD;
      by 3D surface scanning and volumetric analysis will be carried out in the &quot;Landmarker&quot;&#xD;
      software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 19, 2014</start_date>
  <completion_date type="Actual">September 26, 2016</completion_date>
  <primary_completion_date type="Actual">September 26, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-operative bleeding volume (ml)</measure>
    <time_frame>Within 10 minutes after ended surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemostatic profile</measure>
    <time_frame>Baseline, 5.5 hours, 48 hours and 4 months postoperatively</time_frame>
    <description>Changes in the hemostatic profile measured through thrombelastography, thrombin generation test and fibrin structure analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory profile</measure>
    <time_frame>Baseline, 5.5 hours, 48 hours and 4 months postoperatively</time_frame>
    <description>Changes in the inflammatory profile are investigated through measures of surface induced activation, inflammation and plasminogen binding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative edema formation</measure>
    <time_frame>48 hours and 4 months postoperatively</time_frame>
    <description>The degree of postoperative swelling in connection with TXA /or not, is determined by non-invasive 3D face scans and quantified using the &quot;Landmarker&quot; software. Scans are carried out along with the 3rd and 4th blood samples, 48 hours and 4 months postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Intraoperative Bleeding</condition>
  <condition>Postoperative Edema</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Active group:&#xD;
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Tranexamsyre &quot;Pfizer&quot;, D.SP.NR.: 22646, ATC code: B 02 AA 02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo group:&#xD;
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Natriumklorid &quot;B. Braun&quot;, D.SP.NR.: 6856, ATC code: V 07 AB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 18 years or older&#xD;
&#xD;
          -  Patients must be eligible for elective bi-maxillary orthognathic surgery&#xD;
&#xD;
          -  No severe reduction of kidney function&#xD;
&#xD;
          -  No known medical conditions&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  A medical history of acute venous thrombosis and/or arterial thrombosis&#xD;
&#xD;
          -  The presence of fibrinolytic conditions as a result of disseminated intravascular&#xD;
             coagulation, with the exception of a predominant activation of the fibrinolytic system&#xD;
             with acute severe bleeding.&#xD;
&#xD;
          -  Severe kidney deficiency&#xD;
&#xD;
          -  Cramps in the medical history&#xD;
&#xD;
          -  Intake of Omega-3 fatty acids, Gingko Biloba, ginger and garlic supplements within 3&#xD;
             months of surgery.&#xD;
&#xD;
          -  Pregnancy (female participants will be tested on the day of surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper J Olsen, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of South West Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of South West Denmark</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.sydvestjysksygehus.dk/wm385138</url>
    <description>Link to the official site of the maxillofacial surgical department where the study takes place</description>
  </link>
  <reference>
    <citation>Song G, Yang P, Hu J, Zhu S, Li Y, Wang Q. The effect of tranexamic acid on blood loss in orthognathic surgery: a meta-analysis of randomized controlled trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 May;115(5):595-600. doi: 10.1016/j.oooo.2012.09.085. Epub 2012 Dec 20. Review.</citation>
    <PMID>23260768</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of South West Denmark</investigator_affiliation>
    <investigator_full_name>Jesper Jared Olsen</investigator_full_name>
    <investigator_title>DDS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

